SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roger Mathias who wrote (844)12/10/1997 6:00:00 PM
From: EZLibra  Read Replies (1) of 3702
 
Evening all, welcome to SI, Roger.

The chemistry in my background is not adequate to the question but I'll take a stab. Interleukin-13 seems to be another cytokine that may be ultimately useful but is a long way from human studies. There are thousands of toxins that will kill cancer in a petri dish in a lab every time. And mouse studies are not the testing Grail they once were thought to be, cancer not being a model of consistency. To illustrate, a billion dollars was invested in interleukin-2 in the 80's and 90's to find a therapeutic value but one was never found. However, other IL-2 uses generate a few 100 million a year now. Techniclone, as an example, uses IL-2 as a toxin linked to an ab to increase the permeability of a blood vessel prior to delivery of a therapeutic payload. It gives the clinician a choice of increasing dosage and clinical effect 400% or decreasing toxicity four fold. This is the Vasopermeation Enhancement (VE) technology that you will see multiple licenses for next year. Combine VE with the Modified Antibody Technology (MAT) and TNT, and uptake to tumor can increase more than eight fold.

TCLN is always looking for a good agent to deliver to tumors, radiation is used only because to date it is the most efficacious treatment available. If IL-13 completes the long journey back to Bethesda and FDA approval then I would think TCLN would be happy to license it. They have the delivery system.

You asked me to compare IL-13 to radiation, Roger. Kind of hard to do but none of this stuff is actually easy. I hope you understand that in the Glioma trial it's not so much the agent used as it is the viability of the delivery system. It really is a Smart Bomb.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News